OrthO-rheumatO | VOL 11 | Nr 5 | 2013
33
14. kalantar-Zadeh k, kuwae n, regidor dl, et al. survival predictability of time-varying
indicators of bone disease in maintenance hemodialysis patients. kidney int 2006;
70:771-80.
15. Coco m, rush h. increased incidence of hip fractures in dialysis patients with low serum
parathyroid hormone. am j kidney dis 2000;36:1115-21.
16. nussbaum sr, Zahradnik rj, lavigne jr, et al. highly sensitive two-site immunoradiometric
assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin
Chem 1987;33:1364-7.
17. slatopolsky e, finch j, Clay P, et al. a novel mechanism for skeletal resistance in uremia.
kidney int 2000;58:753-61.
18. souberbielle jC, boutten a, Carlier mC, et al. inter-method variability in PTh measurement:
implication for the care of Ckd patients. kidney int 2006;70:345-50.
19. gao P, scheibel s, d'amour P, et al. development of a novel immunoradiometric assay
exclusively for biologically active whole parathyroid hormone 1-84: implications
for improvement of accurate assessment of parathyroid function. j bone miner res
2001;16:605-14.
20. Coen g, bonucci e, ballanti P, et al. PTh 1-84 and PTh "7-84" in the noninvasive diagnosis of
renal bone disease. am j kidney dis 2002;40:348-54.
21. lehmann g, stein g, huller m, schemer r, ramakrishnan k, goodman wg. specific
measurement of PTh (1-84) in various forms of renal osteodystrophy (rod) as assessed by
bone histomorphometry. kidney int 2005;68:1206-14.
22. salusky ib, goodman wg, kuizon bd, et al. similar predictive value of bone turnover using
first- and second-generation immunometric PTh assays in pediatric patients treated with
peritoneal dialysis. kidney int 2003;63:1801-8.
23. Cosman f, morgan dC, nieves jw, et al. resistance to bone resorbing effects of PTh in black
women. j bone miner res 1997;12:958-66.
24. sawaya bP, butros r, naqvi s, et al. differences in bone turnover and intact PTh levels
between african american and Caucasian patients with end-stage renal disease. kidney int
2003;64:737-42.
25. melamed ml, eustace ja, Plantinga lC, et al. Third-generation parathyroid hormone
assays and all-cause mortality in incident dialysis patients: the ChoiCe study. nephrol dial
Transplant 2008;23:1650-8.
26. national kidney foundation. k/doQi clinical practice guidelines for bone metabolism and
disease in chronic kidney disease. am j kidney dis 2003;42:s1-201.
27. Cavalier e, delanaye P, Vranken l, et al. interpretation of serum PTh concentrations with
different kits in dialysis patients according to the kdigo guidelines: importance of the
reference (normal) values. nephrol dial Transplant 2012;27:1950-6.
28. guideline working group. japanese society for dialysis Therapy. Clinical practice guideline for
the management of secondary hyperparathyroidism in chronic dialysis patients. Ther apher
dial 2008;12:514-25.
29. Qunibi w, kalantar-Zadeh k. Target levels for serum phosphorus and parathyroid hormone.
semin dial 2011;24:29-33.
30. gardham C, stevens Pe, delaney mP, leroux m, Coleman a, lamb ej. Variability of
parathyroid hormone and other markers of bone mineral metabolism in patients receiving
hemodialysis. Clin j am soc nephrol 2010;5:1261-7.
31. harris h. The human alkaline phosphatases: what we know and what we don't know. Clin
Chim acta 1990;186:133-50.
32. Cavalier e, delanaye P, Collette j, krzesinski jm, Chapelle jP. evaluation of different bone
markers in hemodialyzed patients. Clin Chim acta 2006;371:107-11.
33. Coen g, ballanti P, balducci a, et al. serum osteoprotegerin and renal osteodystrophy.
nephrol dial Transplant 2002;17:233-8.
34. delanaye P, dubois be, jouret f, krzesinski jm, moranne o, Cavalier e. Parathormone and
bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis
patients: is it so simple? Clin Chim acta 2013;417:35-8.
35. fletcher s, jones rg, rayner hC, et al. assessment of renal osteodystrophy in dialysis
patients: use of bone alkaline phosphatase, bone mineral density and parathyroid
ultrasound in comparison with bone histology. nephron 1997;75:412-9.
36. hutchison aj, whitehouse rw, boulton hf, et al. Correlation of bone histology with
parathyroid hormone, vitamin d3, and radiology in end-stage renal disease. kidney int
1993;44:1071-7.
37. jarava C, armas jr, salgueira m, Palma a. bone alkaline phosphatase isoenzyme in renal
osteodystrophy. nephrol dial Transplant 1996;11(suppl 3):43-6.
38. jean g, souberbielle jC, granjon s, et al. bone biomarkers in haemodialysis patients: bone
alkaline phosphatase or ss-Crosslaps? nephrol Ther 2013;9(3):154-9.
39. jean g, souberbielle jC, Zaoui e, et al. Total and bone-specific alkaline phosphatases in
haemodialysis patients with chronic liver disease. Clin biochem 2012;45:436-9.
40. moore C, yee j, malluche h, et al. relationship between bone histology and markers of bone
and mineral metabolism in african-american hemodialysis patients. Clin j am soc nephrol
2009;4:1484-93.
41. Couttenye mm, d'haese PC, Van hoof Vo, et al. low serum levels of alkaline phosphatase of
bone origin: a good marker of adynamic bone disease in haemodialysis patients. nephrol
dial Transplant 1996;11:1065-72.
42. lehmann g, ott u, kaemmerer d, schuetze j, wolf g. bone histomorphometry and
biochemical markers of bone turnover in patients with chronic kidney disease stages
3 - 5. Clin nephrol 2008;70:296-305.
43. iimori s, mori y, akita w, et al. diagnostic usefulness of bone mineral density and
biochemical markers of bone turnover in predicting fracture in Ckd stage 5d patients--a
single-center cohort study. nephrol dial Transplant 2012;27:345-51.
44. beddhu s, ma X, baird b, Cheung ak, greene T. serum alkaline phosphatase and
mortality in african americans with chronic kidney disease. Clin j am soc nephrol
2009;4:1805-10.
45. blayney mj, Pisoni rl, bragg-gresham jl, et al. high alkaline phosphatase levels in
hemodialysis patients are associated with higher risk of hospitalization and death.
kidney int 2008;74:655-63.
46. kovesdy CP, ureche V, lu jl, kalantar-Zadeh k. outcome predictability of serum alkaline
phosphatase in men with pre-dialysis Ckd. nephrol dial Transplant 2010;25:3003-11.
47. regidor dl, kovesdy CP, mehrotra r, et al. serum alkaline phosphatase predicts mortal-
ity among maintenance hemodialysis patients. j am soc nephrol 2008;19:2193-203.
48. drechsler C, Verduijn m, Pilz s, et al. bone alkaline phosphatase and mortality in dialysis
patients. Clin j am soc nephrol 2011;6:1752-9.
49. kobayashi i, shidara k, okuno s, et al. higher serum bone alkaline phosphatase as a
predictor of mortality in male hemodialysis patients. life sci 2012;90:212-8.
50. Cavalier e, rozet e, Carlisi a, et al. analytical validation of serum bone alkaline phospha-
tase (baP osTase) on liaison. Clin Chem lab med 2010;48:67-72.
51. Cavalier e, delanaye P, Carlisi a, krzesinski jm, Chapelle jP. stability of intact parathyroid
hormone in samples from hemodialysis patients. kidney int 2007;72:370-2.
52. sardiwal s, gardham C, Coleman ae, stevens Pe, delaney mP, lamb ej. bone-specific
alkaline phosphatase concentrations are less variable than those of parathyroid hor-
mone in stable hemodialysis patients. kidney int 2012;82(1):100-5.
53. garrett g, sardiwal s, lamb ej, goldsmith dj. PTh--a particularly tricky hormone: why
measure it at all in kidney patients? Clin j am soc nephrol 2013;8(2):299-312..
54. Vasikaran s, eastell r, bruyere o, et al. markers of bone turnover for the prediction of
fracture risk and monitoring of osteoporosis treatment: a need for international refer-
ence standards. osteoporos int 2011;22:391-420.
55. halleen jm, alatalo sl, suominen h, Cheng s, janckila aj, Vaananen hk. Tartrate-
resistant acid phosphatase 5b: a novel serum marker of bone resorption. j bone miner
res 2000;15:1337-45.
56. nakasato yr, janckila aj, halleen jm, Vaananen hk, walton sP, yam lT. Clinical sig-
nificance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem
1999;45:2150-7.
57. shidara k, inaba m, okuno s, et al. serum levels of TraP5b, a new bone resorption
marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in
hemodialysis patients. Calcif Tissue int 2008;82:278-87.
58. Chu P, Chao Ty, lin yf, janckila aj, yam lT. Correlation between histomorphometric
parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in
uremic patients on maintenance hemodialysis. am j kidney dis 2003;41:1052-9.
59. koivula mk, risteli l, risteli j. measurement of aminoterminal propeptide of type i
procollagen (PinP) in serum. Clin biochem 2012;45:920-7.
60. melkko j, hellevik T, risteli l, risteli j, smedsrod b. Clearance of nh2-terminal propep-
tides of types i and iii procollagen is a physiological function of the scavenger receptor
in liver endothelial cells. j exp med 1994;179:405-12.
61. ueda m, inaba m, okuno s, et al. Clinical usefulness of the serum n-terminal propeptide
of type i collagen as a marker of bone formation in hemodialysis patients. am j kidney
dis 2002;40:802-9.
62. kleerekoper m. biochemical markers of bone remodeling. am j med sci 1996;312:270-7.
63. garnero P, hausherr e, Chapuy mC, et al. markers of bone resorption predict hip fracture
in elderly women: the ePidos Prospective study. j bone miner res 1996;11:1531-8.
64. Qvist P, Christgau s, Pedersen bj, schlemmer a, Christiansen C. Circadian variation in the
serum concentration of C-terminal telopeptide of type i collagen (serum CTx): effects
of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. bone
2002;31:57-61.
65. okabe r, nakatsuka k, inaba m, et al. Clinical evaluation of the elecsys beta-Crosslaps
serum assay, a new assay for degradation products of type i collagen C-telopeptides.
Clin Chem 2001;47:1410-4.
66. reichel h, roth hj, schmidt-gayk h. evaluation of serum beta-carboxy-terminal cross-
linking telopeptide of type i collagen as marker of bone resorption in chronic hemodi-
alysis patients. nephron Clin Pract 2004;98:c112-c118.
67. malyszko j, wolczynski s, Zbroch e, brzosko s, malyszko j, mysliwiec m. serum crosslaps
correlations with serum iCTP and urine dPd in hemodialyzed and peritoneally dialyzed
patients. nephron 2001;87:283-5.
68. negri al, Quiroga ma, bravo m, et al. serum crosslaps as bone resorption marker in
peritoneal dialysis. Perit dial int 2002;22:628-30.
69. graf s, bohne j, hertel a. evaluation of beta-Crosslaps in haemodialysis patients/.
nephrol dial Transplant 2013;18(suppl 4):407.